This page is for HCPs* and ORDMs** in Great Britain. Information on this page is aligned to the Great Britain Summary of Product Characteristics. 
Information about adverse event reporting can be found towards the bottom of the page

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Menu

Close

AboutmRNA TechnologyMechanism of ActionDosing & AdministrationComirnaty Omicron XBB.1.5Dosing & Administration StorageComirnaty Omicron XBB.1.5 30mcg 12 years + (Grey cap)How to OrderComirnaty Omicron XBB.1.5 Supply for Great BritainResourcesMaterialsVideosEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Storage: 12 Years and Older1 

Gray Cap

Purple Cap

COMIRNATY (30 mcg)Storage options

Store in the original package in order to protect from light.

Kicker Header of this card goes here Tab Number 1Tab Number 2Tab Number 4Tab Number 5

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Button Loading

For additional information about the shelf life and storage of this vaccine, please refer to the Summary of Product Characteristics for COMIRNATY (30 mcg), Purple Cap.

*Cartons with an expiry date of December 2021 to March 2022 printed on the label may remain in use for 9 months beyond the printed date (to reflect combined 9-, 12-, and 15-months shelf-life extension), as long as approved storage conditions between -90 °C to -60 °C have been maintained. Cartons with an expiry date of April 2022 through December 2022 printed on the label may remain in use for 6 months beyond the printed date, as long as approved storage conditions between -90 °C to -60 °C have been maintained. For more specific expiry date information, please refer to the Dear Healthcare Professional Letter distributed on <place DHCP-letter dissemination date here and make text black>.
†Refer to the dry ice replenishment guidelines packed in the original thermal shipping container for instructions regarding the use of the thermal shipping container for temporary storage.
COMIRNATY Omicron XBB.1.5 (30 mcg)

Refrigeration1:

  • For use in the private market, single dose vials are provided in cartons of 10
  • The vials will be thawed before delivery
  • Thawed vials can be stored at 2-8°C for up to 10 weeks, within the overall shelf-life of 18 months
  • The original, ultra-low temperature shelf life will have been replaced on the carton by the refrigerated 10 week shelf life
  • This shortened shelf life is marked on the carton only
  • The carton size of one pack of 10 single dose vials is 37 x 47 x 89mm

For additional information about the shelf life and storage, please refer to the Summary of Product Characteristics.
Explore moreDosing & Administration for 12 Years and Older

Learn how to use COMIRNATY Omicron XBB.1.5 30mcg Single Dose Vials.

Loading
ReferencesReferences
Reference:COMIRNATY Omicron XBB.1.5 Single Dose Vial Summary of Product Characteristics
Additional Information

For more details about the other presentations of COMIRNATY Omicron XBB.1.5, for use in the National Immunisation Programme, please refer to the Summary of Product Characteristics or visit the COMIRNATY Education site. 
https://www.comirnatyeducation.co.uk

PP-CMR-GBR-0507. February 2024

Adverse Event Reporting

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. 

Healthcare professionals are asked to report any suspected adverse reactions via a Yellow card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store and include the batch/Lot number if available.

Alternatively, adverse events of concern in association with COMIRNATY can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com.

Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymised form) and dual reporting will create unnecessary duplicates.

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

Marketing Authorisation
Holder: BioNTech
Manufacturing GmbH

COMIRNATY, COMIRNATY Omicron XBB.1.5, are based on BioNTech proprietary mRNA technology, developed by both BioNTech and Pfizer.


The product information provided in this site is intended only for Healthcare Professionals and Other Relevant Decision Makers resident in the United Kingdom. 


This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ.

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-CMR-GBR-0512. January 2024
 

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​